معرفی
Professor Philip Thompson is a leading academic in Medicinal Chemistry at Monash University's Monash Institute of Pharmaceutical Sciences. His research focuses on structure-based drug design, with expertise in kinase inhibitors, epigenetic modulators, and antimicrobial agents. He leads major projects including the development of photo-angioplasty devices and novel therapeutics for diabetes and cancer. Thompson has been honored with prestigious awards for his research impact and collaboration.
Research Interests: Thompson's group specializes in peptides, peptidomimetics, and targeted therapies. Key areas include isoform-selective PI3 kinase inhibitors, PDE inhibitors for parasitic diseases, and polymyxin-based antibacterial agents. His work aligns with UN SDGs related to health and well-being.
- Projects: Includes drug-eluting photo-angioplasty devices for vascular disease, novel therapies for type 1 diabetes, and dual-targeted cancer drugs.
- Awards: Team Award for Research Impact (2016), Vice-Chancellor's Award for Excellence (2022).
- Teaching: Teaches medicinal chemistry courses at Monash, including bio-organic chemistry and pharmacology modules.
Labs & Teams: Thompson collaborates widely on global health initiatives, particularly in antimicrobial resistance and cancer therapeutics. His lab integrates computational methods with synthetic chemistry to accelerate drug discovery.
